News Releases Year: All News20212020201920182017201620152014 Items per page All News2550 Summary ToggleContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH Summary Toggle June 27, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASH Summary Toggle June 20, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering Summary Toggle June 18, 2019 View News Release > Summary ToggleCompelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate Summary Toggle June 17, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B Summary Toggle June 11, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis Summary Toggle June 6, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split Summary Toggle May 31, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision Summary Toggle May 6, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference Summary Toggle April 29, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering Summary Toggle April 25, 2019 View News Release > Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
